Document is current
Any future updates will be listed below
-
Authors
Greten, Tim F. https://orcid.org/0000-0002-0806-2535
Villanueva, Augusto https://orcid.org/0000-0003-3585-3727
Korangy, Firouzeh
Ruf, Benjamin https://orcid.org/0000-0002-2501-4471
Yarchoan, Mark https://orcid.org/0000-0003-4401-0748
Ma, Lichun
Ruppin, Eytan
Wang, Xin W.
- License Information
-
More Information
Article History
Accepted: 29 August 2023
First Online: 19 September 2023
Competing interests
: A.V. has acted as a consultant and/or adviser for Astra Zeneca, BMS, Eisai, FirstWorld, Genentech, Natera, NGM Pharmaceuticals, Pioneering Medicine and Roche; has received research support from Eisai; has stock options from Espervita; and is listed as an inventor on a patent related to early detection of HCC (PCT/US20/61441). M.Y. has acted as a consultant and/or adviser for AstraZeneca, Eisai, Exelixis, Genentech, Hepion and Replimune; has received research funding from Bristol-Myers Squibb, Genentech and Incyte; and holds equity in Adventris Pharmaceuticals. The other authors declare no competing interests.
